Silexion Therapeutics Corp (SLXN) Stock Price, Quote & News

Company Profile

Silexion Therapeutics Corp, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatmen...

Industry: Biotechnology

Sector: Healthcare

Phone: 972 2 674 3430

Fax: 972 2 643 0982

Website: silexion.com

Address:

The Goldyne Savad Inst. of Gene Therapy, Hadassah Hebrew Univ Medical Ctr, Jerusalem, Israel

zeph1985 Aug. 19 at 6:28 AM

$SLXN i feel something

0 · Reply

ShangVXO Aug. 18 at 10:06 AM

Been tapped into @_ProfessorGamma for a minute now. The way they spot some of these plays before they run is nuts! Wise to be paying attention to this account, give him a proper follow 👍 $FGL | $SLXN are underrated

0 · Reply

investing58585 Aug. 16 at 6:56 PM

$LESL $SLXN $IPST your thoughts on $LESL?

0 · Reply

VelmaRosica Aug. 16 at 6:37 PM

Watchlist time... I've got 2 coming off likely bottoms just starting to reverse. $LESL plus $SLXN both low floats worth consideration for a short-term swing. $IPST on HIGH-WATCH tomorrow. Friday closed in strong uptrend. 1.25M float, clean filings, and a history of triple-digit moves and positioned for a huge gap-up on the chart. The only must-watch I see right now. That's all I've got bandwidth for rn. Don't need many, one high-prob banger and two easies, good to go.

0 · Reply

ec017 Aug. 16 at 3:32 PM

$SLXN grimey ass company. Stock trades at dollars post RS until they place warrants at .60 cents for no reason and crash their stock Now after 1 week of being below a dollar they’re asking shareholders to approve 175,000,000 shares at .13 fucking cents ? And another RS approval? Most penny stocks are grimey. But this is just insane. These grimey Israeli companies shouldn’t even be allowed to be public. Insane

0 · Reply

risktaker2016 Aug. 14 at 2:04 PM

$SLXN What an absolute s...show. They are dumping unlimited warrant shares. This is probably going to an RS immediately, without any pumps , anything. The only direction appears to be down. Scam, scam, scam . This is the amazing rate of return for this amazing company ; GL to all bag holders here !

2 · Reply

focafoca99 Aug. 13 at 8:15 PM

$SLXN offered a $2.5 million public offering of shares and warrants, using proceeds to advance the SIL204 trial.

0 · Reply

risktaker2016 Aug. 13 at 2:12 PM

$SLXN At some point they need to remove the algo trading and allow it to maybe go up some 1% at a time, or something. GL to all - maybe this will have a decent pump once in a blue moon or something.

0 · Reply

Imagogetter Aug. 13 at 1:45 PM

$SLXN they gonna run this biatchhhhhhh

0 · Reply

jengtap Aug. 13 at 2:08 AM

$SLXN Offering at $.65. Price Target: $6. How about $2 for now... https://www.tradingview.com/symbols/NASDAQ-SLXN/forecast-price-target/

0 · Reply

Silexion Therapeutics prices $2.5M public offering at $0.65 per share

Aug 14, 2026, 8:45 AM EDT - 5 days ago

Silexion Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

Aug 11, 2026, 8:01 PM EDT - 7 days ago

Silexion Therapeutics Announces Pricing of $2.5 Million Public Offering

2026-08-07T20:45:43.000Z - 11 days ago

Silexion Therapeutics files to sell ordinary shares, warrants, no amount given

Aug 4, 2026, 9:15 AM EDT - 15 days ago

Silexion Therapeutics Reports New Positive Preclinical Findings Demonstrating Multi-Mechanism Immune Sensitization by SIL204 in KRAS-Driven Cancers

2026-07-29T18:15:22.000Z - 20 days ago

Silexion Therapeutics downgraded at Maxim on delisting and dilution risk

2026-07-29T18:05:16.000Z - 20 days ago

Silexion Therapeutics downgraded to Hold from Buy at Maxim

2026-07-29T11:46:29.000Z - 21 days ago

Silexion Therapeutics initiates SIL204 trial

Jul 29, 2026, 7:00 AM EDT - 21 days ago

Silexion Therapeutics Successfully Initiates Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer at Tel Aviv Sourasky Medical Center

Jun 23, 2026, 8:40 AM EDT - 2 months ago

Silexion Therapeutics Receives Approval from Germany's BfArM to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer

Jun 16, 2026, 4:30 PM EDT - 2 months ago

Silexion Therapeutics to Attend BIO International Convention 2026

2026-06-12T20:10:49.000Z - 2 months ago

Silexion Therapeutics files to sell 859,609 ordinary shares for holders

2026-05-28T23:50:59.000Z - 2 months ago

Silexion Therapeutics Corp trading halted, news pending

2026-05-26T14:30:18.000Z - 3 months ago

Silexion Therapeutics announces 1-for-10 reverse share split

May 26, 2026, 8:30 AM EDT - 3 months ago

Silexion Therapeutics Announces 1-for-10 Reverse Share Split

2026-05-21T19:20:55.000Z - 3 months ago

3 Penny Stocks to Watch Now, 5/21/26

HCWB MTVA

May 18, 2026, 8:30 AM EDT - 3 months ago

Silexion Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

May 15, 2026, 8:27 AM EDT - 3 months ago

Silexion Therapeutics Announces Exercise of Warrants for $1 Million Gross Proceeds

May 14, 2026, 9:27 AM EDT - 3 months ago

Silexion Therapeutics Reports Positive Preliminary Immunotherapy Findings for SIL204 in KRAS-Driven Pancreatic Cancer

2026-05-13T16:35:51.000Z - 3 months ago

Silexion Therapeutics initiates GMP clinical batch manufacturing of SIL204

May 13, 2026, 8:00 AM EDT - 3 months ago

Silexion Therapeutics Announces Initiation of GMP Clinical Supply Manufacturing of SIL204 with Leading Global CDMO, and New Approval of Phase 2/3 Trial From Tel Aviv Sourasky Medical Center

2026-04-28T14:13:48.000Z - 4 months ago

Silexion Therapeutics submits SIL204 clinical trial application to Germany

Apr 28, 2026, 8:45 AM EDT - 4 months ago

Silexion Therapeutics Announces Successful Submission of Phase 2/3 Clinical Trial Application to Germany's BfArM for SIL204 in KRAS-Driven Locally Advanced Pancreatic Cancer

2026-03-24T13:50:15.000Z - 5 months ago

Silexion Therapeutics approved to initiate Phase 2/3 clinical trial of SIL204

Mar 24, 2026, 9:46 AM EDT - 5 months ago

Silexion Therapeutics Receives Approval from Israeli Ministry of Health to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer

Mar 17, 2026, 5:01 PM EDT - 5 months ago

Silexion Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

2026-03-05T13:22:21.000Z - 5 months ago

Silexion Therapeutics urges shareholders to vote ahead of EGM

2026-01-06T12:40:28.000Z - 8 months ago

Silexion Therapeutics issues letter to shareholders

2025-12-16T13:45:35.000Z - 8 months ago

Silexion submits Phase 2/3 trial application to Israel for SIL204

Dec 16, 2025, 8:40 AM EST - 8 months ago

Silexion Therapeutics Announces Submission of Phase 2/3 Clinical Trial Application to Israel for SIL204 in Locally Advanced Pancreatic Cancer

2025-12-15T13:00:43.000Z - 8 months ago

Silexion Therapeutics initiated with a Buy at Litchfield Hills

2025-12-02T13:10:13.000Z - 9 months ago

Silexion receives positive feedback from German Health Authority for SIL204

Nov 26, 2025, 7:30 AM EST - 9 months ago

Silexion Therapeutics to Present at Noble Capital Markets' 21st Annual Emerging Growth Equity Conference

2025-11-25T14:20:40.000Z - 9 months ago

Silexion Therapeutics completes toxicology studies for SIL204

Nov 25, 2025, 9:15 AM EST - 9 months ago

Silexion Therapeutics Successfully Completes Toxicology Studies for SIL204, Next-Generation RNA Silencing Therapy, Ahead of Phase 2/3 Clinical Trial in Pancreatic Cancer

2025-11-12T14:06:19.000Z - 10 months ago

Silexion Therapeutics reports Q3 EPS $2.88 vs $274.25 last year

Nov 12, 2025, 9:00 AM EST - 10 months ago

Silexion Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

2025-10-31T21:10:10.000Z - 10 months ago

Silexion Therapeutics files to sell 1.29M ordinary shares for holders

Sep 30, 2025, 8:40 AM EDT - 11 months ago

Silexion Therapeutics Announces Positive New Human Cell Line Data Confirming Pan-KRAS Activity of SIL204, Demonstrating Up to 99.7% Inhibition and First Evidence in Gastric Cancer

Sep 25, 2025, 8:45 AM EDT - 11 months ago

Silexion Therapeutics Regains Compliance with Nasdaq Listing Requirements

Sep 11, 2025, 9:17 AM EDT - 1 year ago

Silexion Therapeutics Announces Pricing of $6.0 Million Public Offering

Sep 11, 2025, 7:00 AM EDT - 1 year ago

Silexion Therapeutics Reports Positive Preclinical Data Demonstrating SIL204's Reach and Activity in Major Pancreatic Cancer Metastatic Sites Following Systemic Administration

Sep 4, 2025, 9:25 AM EDT - 1 year ago

Silexion Therapeutics Announces Selection of Contract Research Organization to Support Upcoming Phase 2/3 Clinical Trials for SIL204

Sep 2, 2025, 8:45 AM EDT - 1 year ago

Silexion Therapeutics to Present at the Upcoming 27th Annual H.C. Wainwright Global Investment Conference

Aug 12, 2025, 8:00 AM EDT - 1 year ago

Silexion Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

Jul 31, 2025, 8:00 PM EDT - 1 year ago

Silexion Therapeutics Announces Exercise of Warrants for $1.8 Million Gross Proceeds

Jul 31, 2025, 9:55 AM EDT - 1 year ago

Silexion Therapeutics Announces New Preclinical Data Showing Up to 97% Inhibition of Cancer Cell Growth, Including New Evidence Against New Previously Untested KRAS Mutation

Jul 16, 2025, 8:44 AM EDT - 1 year ago

Silexion Therapeutics Announces 1-for-15 Reverse Share Split

Jul 9, 2025, 8:30 AM EDT - 1 year ago

Silexion Therapeutics Announces Positive Results in Preclinical Study Demonstrating Significant SIL204 Efficacy in Human Lung Cancer Cell Lines

May 22, 2025, 3:46 PM EDT - 1 year ago

PESG Research Report: A Review of Silexion Therapeutics' Innovative KRAS-Driven Cancer Treatment

May 21, 2025, 8:45 AM EDT - 1 year ago

Silexion Therapeutics Completes Key Preclinical Studies Exploring SIL204's Potential Impact on Colorectal and Lung Cancer

May 13, 2025, 4:45 PM EDT - 1 year ago

Silexion Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Apr 23, 2025, 9:20 AM EDT - 1 year ago

Silexion Therapeutics Announces Collaboration with Global Therapeutics Leader Catalent on Advanced siRNA Formulation Development & Clinical Manufacturing Activities

Mar 28, 2025, 8:30 AM EDT - 1 year ago

Silexion Therapeutics Unveils Innovative Expanded Development Plan for SIL204 Based on Recent Groundbreaking Preclinical Data

Mar 21, 2025, 8:30 AM EDT - 1 year ago

Silexion Therapeutics Announces Completion of Innovative Expanded Development Plan for SIL204 which will be unveiled at the 2025 NeauxCancer Conference

Mar 18, 2025, 4:29 PM EDT - 1 year ago

Silexion Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update

Mar 17, 2025, 8:15 AM EDT - 1 year ago

PESG Report: Silexion Therapeutics' Breakthrough Data Shows SIL204's impact on both Primary Tumors & Metastasis – Signaling a Potential Paradigm Shift in Cancer Treatment

Mar 5, 2025, 8:30 AM EST - 1 year ago

Silexion Therapeutics Reports Groundbreaking Positive Initial Data from Systemic Administration of SIL204 in Orthotopic Pancreatic Cancer Models

Mar 3, 2025, 8:30 AM EST - 1 year ago

PESG Industry Update: Anticipation Rises as Silexion Therapeutics Approaches a Key Preclinical Data That Could Be Transformational

Feb 25, 2025, 8:30 AM EST - 1 year ago

Silexion Therapeutics Announces Completion of Initial Study in Orthotopic Pancreatic Cancer Models Evaluating Systemic Administration of SIL-204

Jan 29, 2025, 5:30 PM EST - 1 year ago

Silexion Therapeutics Announces Exercise of Warrants for $3.3 Million Gross Proceeds

Jan 29, 2025, 9:59 AM EST - 1 year ago

PESG Report: Silexion Therapeutics' Systemic Delivery Breakthrough Positions Company as Rising Star in The Multi-Billion Dollar Precision Oncology Market

Jan 28, 2025, 8:29 AM EST - 1 year ago

Silexion Therapeutics Reports Strong Tumor Growth Reduction from Systemic Administration of SIL-204 in Preclinical Pancreatic Cancer Models

Jan 16, 2025, 11:04 AM EST - 1 year ago

PESG Market Update: Silexion Therapeutics' SIL-204 Shows Groundbreaking Synergy in Preclinical Data, Boosting Hope for KRAS-Driven Cancer Treatments

Jan 15, 2025, 8:00 PM EST - 1 year ago

Silexion Therapeutics Announces Pricing of $5.0 Million Public Offering

Jan 15, 2025, 4:01 PM EST - 1 year ago

Silexion Therapeutics Announces Additional Promising Preclinical Data for SIL-204, Demonstrating Impressive Synergy with First-Line Pancreatic Cancer Chemotherapies

Jan 13, 2025, 7:50 AM EST - 1 year ago

Silexion Therapeutics to Present SIL-204 Data in KRAS-Driven Pancreatic Cancer at the 2025 ASCO Gastrointestinal Cancers Symposium

Dec 17, 2024, 9:36 AM EST - 1 year ago

PESG Releases Market Update: Silexion Therapeutics Advances KRAS-Targeting Therapies with New Collaboration As Industry Demand for Precision Oncology Solutions Rises

AMGN

Nov 22, 2024, 4:30 PM EST - 1 year ago

Silexion Therapeutics Announces 1-for-9 Reverse Share Split

Nov 20, 2024, 8:30 AM EST - 1 year ago

Silexion Therapeutics to Present at the Noble Capital Markets 20th Annual Emerging Growth Equity Conference

zeph1985 Aug. 19 at 6:28 AM

$SLXN i feel something

0 · Reply

ShangVXO Aug. 18 at 10:06 AM

0 · Reply

investing58585 Aug. 16 at 6:56 PM

$LESL $SLXN $IPST your thoughts on $LESL?

0 · Reply

VelmaRosica Aug. 16 at 6:37 PM

0 · Reply

ec017 Aug. 16 at 3:32 PM

0 · Reply

risktaker2016 Aug. 14 at 2:04 PM

2 · Reply

focafoca99 Aug. 13 at 8:15 PM

$SLXN offered a $2.5 million public offering of shares and warrants, using proceeds to advance the SIL204 trial.

0 · Reply

risktaker2016 Aug. 13 at 2:12 PM

$SLXN At some point they need to remove the algo trading and allow it to maybe go up some 1% at a time, or something. GL to all - maybe this will have a decent pump once in a blue moon or something.

0 · Reply

Imagogetter Aug. 13 at 1:45 PM

$SLXN they gonna run this biatchhhhhhh

0 · Reply

jengtap Aug. 13 at 2:08 AM

$SLXN Offering at $.65. Price Target: $6. How about $2 for now... https://www.tradingview.com/symbols/NASDAQ-SLXN/forecast-price-target/

0 · Reply

Zackpedia Aug. 12 at 6:50 PM

$SLXN .48 now!

0 · Reply

SFG1 Aug. 12 at 6:18 PM

$SLXN Now that is interesting....Looks like Mr. M is getting"jiggy" with it.....watch this thing rip now. JMHO

2 · Reply

SFG1 Aug. 12 at 5:24 PM

$SLXN Possible breakout to fill gap above $0.50

0 · Reply

Invescent Aug. 12 at 4:15 PM

📉 $SLXN Top Loser #2 Move: down 56.6% 🔴 Financial Health: Weak • 22/100 🔴 Cash Flow Strength: Weak • Free cash flow -$10.83M 🔴 Profitability: Weak • Net margin 0.0% 🟡 Valuation: Not Meaningful • P/E is not meaningful because earnings are negative; P/S is 0.00 Analysis: Silexion Therapeutics Ltd. shows a weak financial profile. Not financial advice.

1 · Reply

Zackpedia Aug. 12 at 2:27 PM

$SLXN Support at .41

0 · Reply

finviz Aug. 12 at 1:59 PM

The most volatile names today and largest down moves include $PLAG $SNAL and $SLXN

0 · Reply

Dailyfollower Aug. 12 at 1:33 PM

$SLXN is coming 👌

0 · Reply

OpenOutcrier Aug. 12 at 1:00 PM

$SLXN (-57.7% pre) Silexion Therapeutics prices $2.5M public offering at $0.65 per share https://ooc.bz/l/110994

0 · Reply

Dailyfollower Aug. 12 at 12:00 PM

$SLXN I’m going to tell you again, "I told you so."👆👆👆😉

0 · Reply

ec017 Aug. 12 at 11:42 AM

$SLXN paid promoter or delusional? Warrants at .65 and a whole new S-1 active that conveniently doesn’t have any prices or share amounts in it which idk how the SEC even allows that. Scam stock

0 · Reply

Dailyfollower Aug. 12 at 11:32 AM

$SLXN These moves are just for show; don't worry.Add and hold tight 🔥💵🤝

0 · Reply

Dailyfollower Aug. 12 at 11:26 AM

$SLXN Hurry to buy it.👆👆👆😉✍️

0 · Reply

Market Cap	363,000.00
Revenue (ttm)	0.00
Net Income (ttm)	-11.91M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	324,900
Avg Vol	306,888
Day's Range	N/A - N/A
Shares Out	860,000.00
Stochastic %K	3%
Beta	-0.25
Analysts	Sell
Price Target	$60.00